Advertisement
Advertisement
Eupraxia Pharmaceuticals management to meet virtually with Craig-Hallum
PremiumThe FlyEupraxia Pharmaceuticals management to meet virtually with Craig-Hallum
18d ago
Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
Premium
Ratings
Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
1M ago
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
Premium
Company Announcements
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
1M ago
Eupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Announces Major Share Offering to Boost Capital
2M ago
Eupraxia Pharmaceuticals Prices $70 Million Public Offering
Premium
Company Announcements
Eupraxia Pharmaceuticals Prices $70 Million Public Offering
2M ago
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
Premium
The Fly
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
2M ago
Eupraxia Pharmaceuticals’ EP-104GI: A Promising Annual Treatment for Eosinophilic Esophagitis with Significant Market Potential
PremiumRatingsEupraxia Pharmaceuticals’ EP-104GI: A Promising Annual Treatment for Eosinophilic Esophagitis with Significant Market Potential
2M ago
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
Premium
Company Announcements
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
2M ago
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
Premium
The Fly
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100